Bausch Health Companies | VRX - Current Assets


Bausch Health Companies reported $5.98B in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
Amgen USD 31.48B 2.42B Mar/2026
ANI Pharmaceuticals USD 747.08M 6.03M Mar/2026
Aurora Cannabis CAD 445.84M 22M Dec/2025
Bausch Health Companies USD 5.98B 179M Mar/2026
Biogen USD 9.19B 216.3M Mar/2026
Bristol-Myers Squibb USD 27.21B 2.18B Mar/2026
Canopy Growth CAD 524.67M 78.85M Dec/2025
Corcept Therapeutics USD 426.03M 59.43M Mar/2026
Danaher USD 13.94B 1.18B Mar/2026
Drreddys Laboratories INR 3.31B 164.26M Dec/2025
Eli Lilly USD 54.84B 794M Mar/2026
Gilead Sciences USD 18.64B 1.25B Mar/2026
Nektar Therapeutics USD 266.27M 15.09M Dec/2025
Novo Nordisk DKK 177.32B 4.86B Mar/2026
Pacira USD 514.96M 33.01M Mar/2026
Perrigo USD 2.71B 85M Mar/2026
Phibro Animal Health USD 894.07M 31.88M Mar/2026
Prestige Brands USD 431.48M 1.94M Mar/2026
Supernus Pharmaceuticals USD 731.58M 87.4M Mar/2026
Vertex Pharmaceuticals USD 11.73B 529.3M Mar/2026
Zoetis USD 6.47B 294M Mar/2026